Atai Life Sciences spotlights early depression data for psychedelic ahead of big readout
Less than two months after betting $50 million on Beckley Psytech’s psychedelic drugs, atai Life Sciences has shared initial Phase 2a results for one candidate that it says support its use in treatment-resistant depression.
In an open-label study involving 12 patients — 11 of whom were included for analysis — a single dose of Beckley Psytech’s BPL-003 had an antidepressant response on day 2, as measured by the Montgomery–Åsberg Depression Rating Scale. At week 4, 55% of patients were in remission, and 45% were still in remission at week 12, according to atai.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
